Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts

Fig. 2

Adjusted rate of moderate or severe COPD exacerbations (patients with non-reversible airways and EOS < 300 cells/mm3). Bars are adjusted rate (± SE). Treatment comparisons are RR (95% CI). Data analyzed in the mITT population using an efficacy estimand. BFF, budesonide/formoterol fumarate dihydrate; BGF, budesonide/glycopyrronium/formoterol fumarate dihydrate; BUD/FORM, budesonide/formoterol fumarate dihydrate; CI, confidence interval; COPD, chronic obstructive pulmonary disease; EOS, blood eosinophil count; GFF, glycopyrronium/formoterol fumarate dihydrate; mITT, modified intent-to-treat; RR, rate ratio; SE, standard error

Back to article page